menu
    • menu
    [{"orgOrder":0,"company":"BioVie","sponsor":"U.S. Department of Defense","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","year":"2024","type":"Funding","leadProduct":"Bezisterim","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"BioVie","amount2":0.01,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.01,"dosageForm":"","sponsorNew":"BioVie \/ U.S. Department of Defense","highestDevelopmentStatusID":"6","companyTruncated":"BioVie \/ U.S. Department of Defense"},{"orgOrder":0,"company":"BioVie","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Bezisterim","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"BioVie","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"BioVie \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"BioVie \/ Not Applicable"},{"orgOrder":0,"company":"BioVie","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Bezisterim","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"BioVie","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"BioVie \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"BioVie \/ Not Applicable"},{"orgOrder":0,"company":"BioVie","sponsor":"OHRO","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","year":"2024","type":"Funding","leadProduct":"Bezisterim","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"BioVie","amount2":0.01,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"BioVie \/ OHRO","highestDevelopmentStatusID":"14","companyTruncated":"BioVie \/ OHRO"}]

    Find Clinical Drug Pipeline Developments & Deals for Bezisterim

    Menu

    Bezisterim

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            BioVie

                            U.S.A arrow
                            Fi Europe 2024
                            Not Confirmed

                            BioVie

                            U.S.A arrow
                            Fi Europe 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Bezisterim

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase I

                            Sponsor : OHRO

                            Deal Size : $12.6 million

                            Deal Type : Funding

                            DEALS_DEV arrow-down

                            BioVie Secures $12.6M Grant For Long COVID Phase 2 Bezisterim Trial

                            Details : The fundings aims to support BioVie’s to plan the clinical advancement of NE3107 (bezisterim) for the treatment of neurological symptoms that are associated with long COVID.

                            Brand Name : NE3107

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            September 16, 2024

                            Lead Product(s) : Bezisterim

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase I

                            Sponsor : OHRO

                            Deal Size : $12.6 million

                            Deal Type : Funding

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            BioVie

                            U.S.A arrow
                            Fi Europe 2024
                            Not Confirmed

                            BioVie

                            U.S.A arrow
                            Fi Europe 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Bezisterim

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            BioVie Receives FDA Authorization For Bezisterim in Long COVID Phase 2 Trial

                            Details : NE3107 (bezisterim) is an orally bioavailable, BBB-permeable, insulin-sensitizer that is also anti-inflammatory. It is not immunosuppressive and has a low risk of drug-to-drug interaction.

                            Brand Name : NE3107

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            September 03, 2024

                            Lead Product(s) : Bezisterim

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            BioVie

                            U.S.A arrow
                            Fi Europe 2024
                            Not Confirmed

                            BioVie

                            U.S.A arrow
                            Fi Europe 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Bezisterim

                            Therapeutic Area : Neurology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            BioVie Aligns with FDA On Bezisterim Trial For Parkinson’s Disease

                            Details : NE3107 (bezisterim) is an orally bioavailable, BBB-permeable, insulin-sensitizer that is also anti-inflammatory. It is being evaluated for the treatment of parkinson's disease.

                            Brand Name : NE3107

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            August 08, 2024

                            Lead Product(s) : Bezisterim

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            BioVie

                            U.S.A arrow
                            Fi Europe 2024
                            Not Confirmed

                            BioVie

                            U.S.A arrow
                            Fi Europe 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Bezisterim

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase I

                            Sponsor : U.S. Department of Defense

                            Deal Size : $13.1 million

                            Deal Type : Funding

                            DEALS_DEV arrow-down

                            BioVie Awarded Up to $13.1M from DoD to Study Bezisterim for Long COVID

                            Details : The funding is intended to support the clinical advancement of the company's investigational product NE3107 (bezisterim), which is currently undergoing evaluation in early-stage trials for Covid-19.

                            Brand Name : NE3107

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            April 29, 2024

                            Lead Product(s) : Bezisterim

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase I

                            Sponsor : U.S. Department of Defense

                            Deal Size : $13.1 million

                            Deal Type : Funding

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth